ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-OR004

AKI and Electrolyte Abnormalities in Patients Receiving Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Session Information

Category: Onco-Nephrology

  • 1500 Onco-Nephrology


  • Gupta, Shruti, BWH, Boston, Massachusetts, United States
  • Seethapathy, Harish Shanthanu, Massachusetts General Hospital, Boston, Massachusetts, United States
  • Motwani, Shveta S., Brigham and Women's Hospital and Dana-Farber Cancer Institute, Newton, Massachusetts, United States
  • Parikh, Samir M., BIDMC/Harvard Medical School, Boston, Massachusetts, United States
  • Curhan, Gary C., Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States
  • Reynolds, Kerry, Massachusetts General Hospital, Boston, Massachusetts, United States
  • Leaf, David E., Brigham and Women's Hospital, Boston, Massachusetts, United States
  • Sise, Meghan E., Massachusetts General Hospital, Boston, Massachusetts, United States

CAR-T therapy targets tumor antigens using genetically engineered cytotoxic T-cells, and is a breakthrough treatment for hematologic malignancies. Cytokine release syndrome (CRS), a systemic inflammatory response, is a known complication of CAR-T. CRS can lead to acute kidney injury (AKI); however, scant data exist on AKI in adults. We aimed to define the incidence, clinical features, and outcomes of AKI and electrolyte abnormalities in adults receiving CAR-T.


We performed a retrospective review of adults with lymphoma treated with CAR-T at 2 major cancer centers in Boston. Baseline demographics, laboratory data, and clinical outcomes were obtained from electronic health records. AKI was defined using KDIGO criteria.


Among 78 patients receiving CAR-T, CRS occurred in 85%, of whom 62% required treatment with tocilizumab. AKI occurred in 15 patients (19%): 8 were pre-renal azotemia; 6 acute tubular necrosis; and 1 urinary obstruction related to disease progression. Patients with AKI were more likely to experience higher grades of CRS (grades 3,4). The association between the underlying cause of AKI and length of stay (LOS)/mortality are shown in Figure 1. All 3 patients requiring dialysis died during the hospitalization during which they received CAR-T. Electrolyte abnormalities in the first week after CAR-T were common: hypophosphatemia < 2.0 mg/dL occurred in 51% and hyponatremia < 130mEq/L in 15%.


In the largest report of adverse kidney events associated with CAR-T in adults, AKI and electrolyte abnormalities occur commonly in the context of CRS.


  • NIDDK Support